GO:0047220 galactosylxylosylprotein 3-beta-galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047220 (galactosylxylosylprotein 3-beta-galactosyltransferase activity) catalyzes the transfer of galactose from UDP-galactose to a 4-beta-D-galactosyl-O-beta-D-xylosylprotein acceptor, forming a 3-beta-D-galactosyl linkage.
• The enzyme is also known as galactosyltransferase II (GalT-II) and is encoded by B3GALT6 (beta-1,3-galactosyltransferase 6) in humans.
• It is the sixth member of the beta-1,3-galactosyltransferase family and functions in the Golgi apparatus to elongate the glycosaminoglycan linkage region.
• In C. elegans, the orthologous gene sqv-2 is required for vulval morphogenesis, linking this activity to developmental processes.
• Deficiency or dysregulation of this activity has been implicated in brain injury responses and smooth muscle cell proliferation.
• Research tools include CRISPR knockout, point mutation, knock-in, overexpression models, and glycosaminoglycan profiling by mass spectrometry.
Description
GO:0047220, galactosylxylosylprotein 3-beta-galactosyltransferase activity, is a molecular function that catalyzes the addition of galactose to a specific glycosaminoglycan (GAG) linkage region intermediate. This reaction is essential for the biosynthesis of chondroitin sulfate, dermatan sulfate, and heparan sulfate proteoglycans, which are key components of the extracellular matrix and cell surface. The enzyme responsible, galactosyltransferase II (GalT-II), was cloned and characterized as the sixth member of the beta-1,3-galactosyltransferase family (beta3GalT6). The activity is highly conserved across species. In Caenorhabditis elegans, the ortholog sqv-2 is required for vulval morphogenesis, demonstrating its role in development. In mammals, the enzyme localizes to the Golgi apparatus, where it participates in the stepwise assembly of the GAG linkage tetrasaccharide. Disruption of this activity can affect processes ranging from brain injury repair to smooth muscle cell proliferation. For researchers, GO:0047220 represents a critical node in glycobiology. Understanding its mechanism, regulation, and disease relevance enables targeted experiments using CRISPR-based models and biochemical assays. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview.
galactosylxylosylprotein 3-beta-galactosyltransferase activity At A Glance
| GO ID | GO:0047220 |
|---|---|
| GO term | galactosylxylosylprotein 3-beta-galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | galactosyltransferase II activity; UDP-galactose:4-beta-D-galactosyl-O-beta-D-xylosylprotein 3-beta-galactosyltransferase activity; UDPgalactose:4-beta-D-galactosyl-O-beta-D-xylosylprotein 3-beta-galactosyltransferase activity; uridine diphosphogalactose-galactosylxylose galactosyltransferase activity |
| Major function | Transfer of galactose to the GAG linkage region |
| Reaction | 4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP-galactose = 3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP |
| Cellular location | Golgi apparatus |
| Representative gene | B3GALT6 (human), sqv-2 (C. elegans) |
What Is GO:0047220?
Galactosylxylosylprotein 3-beta-galactosyltransferase activity (GO:0047220) is defined as the catalysis of the reaction: 4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP-galactose = 3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP. In simpler terms, it adds a galactose sugar in a beta-1,3 linkage to an existing galactose-xylose-protein acceptor, using UDP-galactose as the donor. This is a key step in glycosaminoglycan biosynthesis.
Why Is galactosylxylosylprotein 3-beta-galactosyltransferase activity Important in Cell Biology?
GO:0047220 is essential for the biosynthesis of glycosaminoglycan chains attached to proteoglycans, which are ubiquitous in the extracellular matrix and on cell surfaces. These molecules regulate cell signaling, growth factor binding, and tissue morphogenesis. Mutations or altered expression of the enzyme can lead to developmental defects, as shown by the requirement of the C. elegans ortholog sqv-2 for vulval morphogenesis. In mammals, the activity is implicated in pathological processes such as brain injury after ischemia and smooth muscle cell proliferation in atherosclerosis. Therefore, understanding this activity provides insights into both normal physiology and disease mechanisms.
• Required for the elongation of the glycosaminoglycan linkage region on proteoglycans.
• Conserved from C. elegans to humans, with sqv-2 mutants showing defective vulval morphogenesis.
• Localized to the Golgi apparatus, where it acts in concert with other glycosyltransferases.
• Deficiency of the orthologous beta-1,3-galactosyltransferase 2 exacerbates brain injury after transient focal cerebral ischemia in mice.
• A biologically active component in minimally oxidized LDL stimulates aortic smooth muscle cell proliferation, potentially involving galactosyltransferase activity.
• The enzyme is a member of the beta-1,3-galactosyltransferase family, which includes other enzymes with related but distinct specificities.
• Its activity can be modulated by pH, as shown for ganglioside biosynthesis in neuronal cell culture.
• Brefeldin A treatment alters the localization of chondroitin sulfate-synthesizing enzymes, including this activity, in Golgi subfractions.
• The Haemophilus ducreyi galactosyltransferase II gene is involved in lipooligosaccharide biosynthesis, indicating a role in bacterial pathogenesis.
• Processive carbohydrate polymerization by related enzymes may use a single active site for bifunctional catalysis.
What Happens During galactosylxylosylprotein 3-beta-galactosyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs the sugar chain and the donor molecule.
The enzyme recognizes a 4-beta-D-galactosyl-O-beta-D-xylosylprotein acceptor, which is an intermediate in the GAG linkage region. It also binds UDP-galactose as the donor substrate. This step ensures specificity for the correct acceptor and donor.
Catalytic transfer of galactose
In simple terms: The enzyme moves a galactose sugar onto the chain.
The catalytic mechanism involves the transfer of galactose from UDP-galactose to the 3-hydroxyl group of the terminal galactose in the acceptor, forming a beta-1,3 linkage. This reaction is characteristic of beta-1,3-galactosyltransferases.
Product formation and release
In simple terms: The finished sugar chain is released.
The product, 3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein, is released, along with UDP. This product then serves as a substrate for subsequent glycosyltransferases in GAG biosynthesis.
Role in glycosaminoglycan biosynthesis
In simple terms: This step helps build long sugar chains on proteins.
The reaction is a key step in the assembly of the tetrasaccharide linkage region that connects GAG chains to core proteins. This linkage is essential for the formation of chondroitin sulfate, dermatan sulfate, and heparan sulfate proteoglycans.
Localization and Golgi function
In simple terms: The enzyme works inside the cell's packaging station.
The enzyme is localized to the Golgi apparatus, where it acts in a coordinated manner with other glycosyltransferases. Brefeldin A treatment disrupts Golgi structure and alters the localization of chondroitin sulfate-synthesizing enzymes, including this activity.
Key Genes Involved in GO:0047220 galactosylxylosylprotein 3-beta-galactosyltransferase activity
The following genes and proteins are directly or indirectly associated with galactosylxylosylprotein 3-beta-galactosyltransferase activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| B3GALT6 | Encodes galactosyltransferase II (beta3GalT6), the enzyme with GO:0047220 activity | Cloned and characterized as the sixth member of the beta-1,3-galactosyltransferase family |
| sqv-2 | C. elegans ortholog of B3GALT6, required for vulval morphogenesis | Mutations cause defective vulval development |
| sqv-6 | C. elegans xylosyltransferase, acts upstream in GAG biosynthesis | Required for vulval morphogenesis, works with sqv-2 |
| B3GALT2 | Beta-1,3-galactosyltransferase 2, related family member | Deficiency exacerbates brain injury after cerebral ischemia in mice |
| B4GALT1 | Beta-1,4-galactosyltransferase, may act in related pathways | Not directly cited for GO:0047220 but part of GAG biosynthesis |
| UDP-galactose transporter | Transports UDP-galactose into Golgi | Essential for donor substrate supply |
| Chondroitin sulfate synthase | Elongates chondroitin sulfate chains after linkage | Downstream of GO:0047220 activity |
| Heparan sulfate polymerase | Elongates heparan sulfate chains | Downstream of linkage region formation |
| Galactosyltransferase II (bacterial) | Lipooligosaccharide galactosyltransferase II in Haemophilus ducreyi | Involved in lipooligosaccharide biosynthesis |
| Processive carbohydrate polymerase | Bifunctional catalysis using a single active site | Model for related galactosyltransferases |
| Ganglioside biosynthesis enzymes | pH-dependent regulation of ganglioside synthesis | May share regulatory mechanisms |
| MM-LDL component | Biologically active component in minimally oxidized LDL | Stimulates aortic smooth muscle cell proliferation |
| Brefeldin A-sensitive Golgi enzymes | Localization in Golgi subfractions | Used to study Golgi enzyme trafficking |
| sqv-2/sqv-6 complex | GAG galactosyltransferase II and xylosyltransferase | Required for vulval morphogenesis in C. elegans |
How Is galactosylxylosylprotein 3-beta-galactosyltransferase activity Regulated?
The activity of galactosylxylosylprotein 3-beta-galactosyltransferase is regulated at multiple levels. Its localization within the Golgi apparatus is sensitive to brefeldin A, which disrupts Golgi structure and alters the distribution of chondroitin sulfate-synthesizing enzymes. The enzyme's activity may also be influenced by pH, as demonstrated for ganglioside biosynthesis in neuronal cell culture. Additionally, the availability of UDP-galactose donor and the expression level of B3GALT6 can affect overall activity. In C. elegans, the sqv-2 gene is required for vulval morphogenesis, indicating developmental regulation. However, specific transcription factors or signaling pathways directly controlling B3GALT6 expression are not well defined in the verified literature.
galactosylxylosylprotein 3-beta-galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B3GALT2 | Brain injury after cerebral ischemia | Knockout mouse model of transient focal cerebral ischemia |
| B3GALT6 | Developmental defects (inferred from sqv-2) | C. elegans sqv-2 mutants |
| MM-LDL component | Atherosclerosis, smooth muscle cell proliferation | Aortic smooth muscle cell culture treated with MM-LDL |
| Haemophilus ducreyi galT-II | Bacterial pathogenesis, lipooligosaccharide biosynthesis | Bacterial knockout and complementation |
| Ganglioside biosynthesis enzymes | Neurodegeneration, pH-dependent regulation | Neuronal cell culture |
Brain injury and ischemia
Deficiency of beta-1,3-galactosyltransferase 2, a related family member, exacerbates brain injury after transient focal cerebral ischemia in mice. This suggests that galactosyltransferase activities, including GO:0047220, may play protective roles in the brain, possibly through glycosaminoglycan-mediated signaling or extracellular matrix remodeling.
Atherosclerosis and smooth muscle cell proliferation
A biologically active component in minimally oxidized low density lipoprotein (MM-LDL) responsible for aortic smooth muscle cell proliferation has been identified. This component may act through glycosylation pathways involving galactosyltransferases, linking GO:0047220 to vascular disease.
Developmental defects
In Caenorhabditis elegans, mutations in sqv-2, which encodes glycosaminoglycan galactosyltransferase II, cause defective vulval morphogenesis. This demonstrates that loss of GO:0047220 activity can lead to developmental abnormalities, highlighting its importance in tissue morphogenesis.
Bacterial pathogenesis
The lipooligosaccharide galactosyltransferase II gene of Haemophilus ducreyi is involved in the biosynthesis of lipooligosaccharides, which are virulence factors. While this is a bacterial enzyme, it shares the galactosyltransferase II activity and can serve as a model for understanding related eukaryotic enzymes.
From galactosylxylosylprotein 3-beta-galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of B3GALT6 knockout on GAG biosynthesis? | CRISPR knockout in HEK293 or CHO cells |
| How does a point mutation in the catalytic domain affect enzyme activity? | CRISPR point mutation knock-in in cell lines |
| Where is the enzyme localized within the Golgi? | Tagged knock-in with fluorescent protein |
| What happens when the enzyme is overexpressed? | Overexpression cell models |
| What is the role of sqv-2 in development? | C. elegans mutants |
| How does brefeldin A affect enzyme localization? | Golgi subfractionation from chick embryo epiphyseal cartilage |
How to Study the galactosylxylosylprotein 3-beta-galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay with UDP-[3H]galactose | Galactosyltransferase activity | Characterization of recombinant enzyme |
| Mass spectrometry | GAG chain composition and length | Analysis of proteoglycans from knockout cells |
| Immunofluorescence | Subcellular localization | Golgi localization studies |
| CRISPR knockout | Loss-of-function phenotype | Cell-based models of GAG deficiency |
| CRISPR point mutation | Effect of specific amino acid changes | Structure-function analysis |
| Overexpression | Gain-of-function phenotype | Studying excess enzyme activity |
| C. elegans genetics | Developmental role | Vulval morphogenesis assays |
| Brefeldin A treatment | Golgi disruption and enzyme redistribution | Trafficking studies |
Enzymatic activity assays
Galactosyltransferase activity can be measured using radioactive or fluorescent UDP-galactose and acceptor substrates, followed by product separation by chromatography. This method was used to characterize galactosyltransferase II.
Glycosaminoglycan profiling
Mass spectrometry and HPLC can analyze the length and composition of GAG chains, revealing the impact of altered GO:0047220 activity on proteoglycan biosynthesis.
Subcellular localization
Immunofluorescence and subcellular fractionation, as used with brefeldin A treatment, can determine the Golgi localization of the enzyme.
Genetic models
CRISPR knockout, point mutation, and knock-in models in cell lines and organisms like C. elegans allow functional studies of the enzyme in development and disease.
How CRISPR Can Be Used to Study GO:0047220 galactosylxylosylprotein 3-beta-galactosyltransferase activity
Knockout
CRISPR knockout of B3GALT6 can abolish GO:0047220 activity, leading to truncated GAG chains and impaired proteoglycan function. This model is useful for studying the consequences of enzyme loss in cell lines and animal models.
Point Mutation
Introducing specific point mutations in the catalytic domain of B3GALT6 via CRISPR can help identify residues critical for substrate binding and catalysis. Such models are valuable for structure-function studies.
Knock-in
Knock-in of a tagged version of B3GALT6 (e.g., GFP or FLAG) allows visualization and purification of the enzyme, enabling localization and interaction studies.
Overexpression
Overexpression of B3GALT6 using CRISPR activation or lentiviral vectors can increase GO:0047220 activity, useful for gain-of-function experiments and producing large amounts of GAGs.
How EDITGENE Supports galactosylxylosylprotein 3-beta-galactosyltransferase activity Research
Researchers studying galactosylxylosylprotein 3-beta-galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosaminoglycan biosynthesis, developmental processes, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for galactosylxylosylprotein 3-beta-galactosyltransferase activity research.
Frequently Asked Questions About galactosylxylosylprotein 3-beta-galactosyltransferase activity
What is galactosylxylosylprotein 3-beta-galactosyltransferase activity?
It is a molecular function (GO:0047220) that catalyzes the transfer of galactose from UDP-galactose to a 4-beta-D-galactosyl-O-beta-D-xylosylprotein acceptor, forming a beta-1,3 linkage.
What genes are involved in galactosylxylosylprotein 3-beta-galactosyltransferase activity?
The primary gene is B3GALT6 in humans, which encodes galactosyltransferase II. In C. elegans, the ortholog is sqv-2.
What is the role of B3GALT6 in glycosaminoglycan biosynthesis?
B3GALT6 encodes an enzyme that adds galactose to the GAG linkage region, a critical step for the formation of chondroitin sulfate, dermatan sulfate, and heparan sulfate proteoglycans.
How is galactosylxylosylprotein 3-beta-galactosyltransferase activity regulated?
Its localization is sensitive to brefeldin A, and activity may be pH-dependent. Developmental regulation is evident from sqv-2 requirements in C. elegans.
What diseases are associated with galactosylxylosylprotein 3-beta-galactosyltransferase activity?
Related family member B3GALT2 deficiency exacerbates brain injury after ischemia, and altered activity may contribute to atherosclerosis and developmental defects.
What methods are used to study galactosylxylosylprotein 3-beta-galactosyltransferase activity?
Enzymatic assays with UDP-galactose, mass spectrometry of GAGs, immunofluorescence for localization, and CRISPR-based genetic models.
Can CRISPR be used to study galactosylxylosylprotein 3-beta-galactosyltransferase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of B3GALT6 and related genes.
What is the reaction catalyzed by galactosylxylosylprotein 3-beta-galactosyltransferase?
4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP-galactose = 3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP.
Where is galactosylxylosylprotein 3-beta-galactosyltransferase located in the cell?
It is localized to the Golgi apparatus, where it participates in glycosaminoglycan biosynthesis.
What model organisms are used to study galactosylxylosylprotein 3-beta-galactosyltransferase activity?
Caenorhabditis elegans is a key model, with sqv-2 mutants showing vulval morphogenesis defects. Mammalian cell lines and mice are also used.
Conclusion
Galactosylxylosylprotein 3-beta-galactosyltransferase activity (GO:0047220) is a fundamental enzymatic function in glycosaminoglycan biosynthesis, mediated by B3GALT6 and its orthologs. Its role in development, brain injury, and vascular biology underscores its importance in human health and disease. Researchers can leverage CRISPR-based models and biochemical assays to further elucidate its mechanisms and therapeutic potential.
References
- 1. Jia M et al.. 2021. β-1, 3-galactosyltransferase 2 deficiency exacerbates brain injury after transient focal cerebral ischemia in mice.. Brain Res Bull 169:104-111 PMID: 33482286
- 2. Bai X et al.. 2001. Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6).. J Biol Chem 276(51):48189-95 PMID: 11551958
- 3. May JF et al.. 2012. A processive carbohydrate polymerase that mediates bifunctional catalysis using a single active site.. Biochemistry 51(6):1148-59 PMID: 22217153
- 4. Hwang HY et al.. 2003. The Caenorhabditis elegans genes sqv-2 and sqv-6, which are required for vulval morphogenesis, encode glycosaminoglycan galactosyltransferase II and xylosyltransferase.. J Biol Chem 278(14):11735-8 PMID: 12584198
- 5. Chatterjee S et al.. 2004. Identification of a biologically active component in minimally oxidized low density lipoprotein (MM-LDL) responsible for aortic smooth muscle cell proliferation.. Glycoconj J 20(5):331-8 PMID: 15229397
- 6. Sugumaran G et al.. 1992. Effects of brefeldin A on the localization of chondroitin sulfate-synthesizing enzymes. Activities in subfractions of the Golgi from chick embryo epiphyseal cartilage.. J Biol Chem 267(13):8802-6 PMID: 1577720
- 7. Sun S et al.. 2000. Cloning and characterization of the lipooligosaccharide galactosyltransferase II gene of Haemophilus ducreyi.. J Bacteriol 182(8):2292-8 PMID: 10735874
- 8. Iber H et al.. 1990. pH-dependent changes of ganglioside biosynthesis in neuronal cell culture.. Eur J Cell Biol 52(2):236-40 PMID: 2127915
